The Food and Drug Administration last week authorized extending the shelf life to 12 months for two formulations of the Pfizer COVID-19 vaccine when stored at -130ºF to -76ºF. For more information, see the April 13 fact sheets for health care providers.  

The FDA and Health and Human Services Office of the Assistant Secretary for Preparedness and Response also are considering extending the shelf life for the combination monoclonal antibodies bamlanivimab and/or etesevimab, and plan to issue an update in early May. Until then, health care providers may retain all unopened bamlanivimab and etesevimab vials that were stored at 36°F to 46°F as detailed in the authorization letter and fact sheet for providers, HHS said.

Bamlanivimab and etesevimab are not currently authorized in any U.S. region due to the omicron variant’s prevalence, but the agencies recommend retaining the product in case future variants are susceptible to the treatment. 

Related News Articles

Headline
The Food and Drug Administration does not currently authorize the monoclonal antibody bamlanivimab for emergency use to treat mild-to-moderate COVID-19 in the…
Headline
In a study of symptomatic adults tested for SARS-CoV-2 at U.S. pharmacies since Sept. 14, bivalent COVID-19 vaccine boosters provided additional protection…
Headline
The Biden Administration today launched a six-week campaign to encourage Americans to get an updated COVID-19 vaccine. In addition to ongoing pop-up clinics,…
Headline
Children under age 5 are more likely to receive a COVID-19 vaccine if their parents perceive it as safe and their health care provider recommends it, according…
Headline
AHA this week released a new Thanksgiving-focused toolkit to help promote pediatric COVID-19 vaccination on social media, including sample content and graphics…
Headline
The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected…